PulteGroup Inc. (PHM)

30.14
0.49 1.70
NYSE : Consumer Durables
Prev Close 29.65
Open 29.43
Day Low/High 29.40 / 30.17
52 Wk Low/High 23.81 / 35.21
Volume 5.13M
Avg Volume 4.30M
Exchange NYSE
Shares Outstanding 285.52M
Market Cap 8.46B
EPS 1.40
P/E Ratio 16.93
Div & Yield 0.36 (1.22%)

Latest News

Analyst Favorites With Strong Buyback Activity: PulteGroup Ranks As A Top Pick

Analyst Favorites With Strong Buyback Activity: PulteGroup Ranks As A Top Pick

A study of analyst recommendations at the major brokerages shows that PulteGroup Inc is the #39 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

PulteGroup's Second Quarter 2018 Earnings Conference Call To Begin At 8:00 A.M. On July 26, 2018

PulteGroup's Second Quarter 2018 Earnings Conference Call To Begin At 8:00 A.M. On July 26, 2018

PulteGroup, Inc. (NYSE: PHM) today announced that the start time for the Company's conference call to discuss second quarter 2018 financial results has been changed to 8:00 a.

PulteGroup's Second Quarter 2018 Earnings Release And Webcast Conference Call Scheduled For July 26, 2018

PulteGroup's Second Quarter 2018 Earnings Release And Webcast Conference Call Scheduled For July 26, 2018

PulteGroup, Inc. (NYSE: PHM) today announced that it will release its second quarter 2018 financial results before the market opens on Thursday, July 26, 2018.

PharmaMar And Chugai Agree To Terms For Early Termination Of The License Agreement For Zepsyre® In Japan

PharmaMar And Chugai Agree To Terms For Early Termination Of The License Agreement For Zepsyre® In Japan

MADRID, June 26, 2018 /PRNewswire/ -- PharmaMar regains all its rights for Zepsyre ® in Japan with immediate effec t and receives a payment of € 3,000, 000 from Chugai  PharmaMar progresses in the clinical development of Zepsyre ® in Japan while its...

Life Tested, Now Connected

Life Tested, Now Connected

Enviable design, quality construction, desirable locations and ample choices are why homeowners for decades have chosen to build their dream home with PulteGroup.

PulteGroup Has Broken Out on the Upside

PulteGroup Has Broken Out on the Upside

Charts suggest shares of home builder are headed higher.

PharmaMar Signs A Commercialization And Distribution License Agreement For Aplidin® With Pint Pharma International

PharmaMar Signs A Commercialization And Distribution License Agreement For Aplidin® With Pint Pharma International

MADRID, June 11, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.

Del Webb Announces Grand Opening Of Highly-Anticipated Rancho Mirage Community (Photo: Business Wire)

Del Webb Announces Grand Opening Of Highly-Anticipated Rancho Mirage Community (Photo: Business Wire)

Del Webb, the nation's leading builder of active adult communities, has scheduled the grand opening of its Rancho Mirage community for June 9, 2018.

PharmaMar Presents In Oral Session At ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin

PharmaMar Presents In Oral Session At ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin

MADRID, June 5, 2018 /PRNewswire/ -- Abstract #8018  The modelled data on overall survival of the statistical evaluation of the impact of crossover on the ADMYRE study were presented .

PharmaMar Presents New Results With Lurbinectedin As A Single Agent In Patients With Recurrent Small-cell Lung Cancer At ASCO 2018

PharmaMar Presents New Results With Lurbinectedin As A Single Agent In Patients With Recurrent Small-cell Lung Cancer At ASCO 2018

MADRID, June 4, 2018 /PRNewswire/ -- Abstract #8570 The phase II basket trial, which began recruiting 15 patients with recurrent small-cell lung cancer, was increased to target enrolment of 100 after obtaining a positive response.

PulteGroup Becomes #98 Most Shorted S&P 500 Component, Replacing Mylan

The most recent short interest data has been released for the 05/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Jim Cramer: Homebuilder, Consumer Packaged Goods Stocks Face the 'New' Bad

Jim Cramer: Homebuilder, Consumer Packaged Goods Stocks Face the 'New' Bad

These stocks are like spewing volcanoes. You do not want to get hit by one of them.

PulteGroup Announces Quarterly Cash Dividend Of $0.09 Per Share

PulteGroup Announces Quarterly Cash Dividend Of $0.09 Per Share

PulteGroup, Inc. (NYSE: PHM) announced today that its Board of Directors has declared a quarterly cash dividend of $0.

IIROC Trading Resumption - PHM; PHM.DB

Novice Trade: PulteGroup

Novice Trade: PulteGroup

A PHM bullishly biased, out-of-the-money vertical call spread expiring in July.

IIROC Trading Halt - PHM.DB

PulteGroup's Presentation At The J.P. Morgan Homebuilding & Building Products Conference To Be Webcast Live

PulteGroup's Presentation At The J.P. Morgan Homebuilding & Building Products Conference To Be Webcast Live

PulteGroup, Inc. (NYSE: PHM), will present at the J.

Jim Cramer's 7 Deadly Sins That Can Kill Your Stocks

Jim Cramer's 7 Deadly Sins That Can Kill Your Stocks

Expert unveils these key risk factors at TheStreet's Boot Camp for Investors in New York.

Sylentis Presented New Results For The Treatment Of Age Associated Macular Degeneration

Topical administration of siRNA could be a new therapeutic option for the treatment of degenerative illnesses of the retina that presents processes of neovascularization[i].

Jim Cramer: Repeal of All of the Gains We Are Seeing Makes No Real Sense

Jim Cramer: Repeal of All of the Gains We Are Seeing Makes No Real Sense

The idea that the tax changes have done nothing is, indeed, fanciful.

Novice Trade: ITB Home Construction ETF

Novice Trade: ITB Home Construction ETF

A bullishly biased, ITB out-of-the-money long call 'shooter' expiring in July.

First-Quarter Earnings Highlights

First-Quarter Earnings Highlights

Homebuilders and industrial names are seeing good results.

TheStreet Quant Rating: B+ (Buy)